Antipsychotic-induced Extrapyramidal Syndromes in Psychiatric Practice: A Case-control Study
- 48 Downloads
Background: While several clinical trials showed that atypical antipsychotics have a low risk of extrapyramidal side effects (EPS), this observation is not undisputed. This study compared the risk of EPS between specific subgroups of antipsychotics.
Methods: Using the automated dispensing records of a large psychiatric hospital in The Netherlands, we defined cases as first-time users of anticholinergic antiparkinson drugs. Controls were all patients with no recorded use of such medication. Cases and controls were compared with regard to previous use of antipsychotics and relevant co-factors.
Results: Out of 1403 patients, we identified 105 cases and 330 controls. Compared to non-users, antipsychotic-users were 10 times more likely to start with anticholinergic antiparkinson medication (adjusted odds ratio: 10.1; 95 CI 4.6–22.3). Depot and non-depot antipsychotics had similar adjusted odds ratios of 10.9 (95 CI 3.7–32.6) and 8.8 (95% CI 3.8–20.4) respectively. Low and high potency antipsychotics gave odds ratios of 3.0 (95% CI 0.9–10.3) versus 10.8 (95% CI 4.7–25.1). Classical and atypical antipsychotics showed comparable odds ratios: 10.0 (95% CI: 4.4–22.5) versus 8.0 (95% CI: 2.6–24.5). Applied doses of classical and atypical antipsychotic drugs were much lower and more equivalent than those used in previous clincial trials.
Conclusions: Low potency antipsychotics had a much lower risk of EPS than other antipsychotics. However, we did not corroborate the reduced risk with atypical antipsychotics observed in several clinical trials. This discrepancy may result from the high and non-equivalent doses of classical antipsychotics used in many of these trials.
Key wordsADRs Antipsychotics Atypical antipsychotics Extrapyramidal syndromes Parkinsonism Schizophrenia Side effect
Unable to display preview. Download preview PDF.
- 1.Murray, CJL, Lopez, AD. 1996The Global Burden of Disease and Injury Series, Vol 1: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020Harvard University PressCambridge, MAGoogle Scholar
- 2.Gijsen R, Roos MJC. Hoe vaak komt schizofrenie voor? In: Volksgezondheid toekomst verkenning, Nationaal kompas volksgezondheid. Bilthoven: RIVM, 2004.Google Scholar
- 10.Miller, CH, et al. 1998The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychoticsJ Clin Psychiatry596975Google Scholar
- 12.Standaert, DG, Young, AB. 1995Treatment of central nervous system degenerative disordersGoodman, LSGilman, AHardman, JGGilman, AGLimbird, LE eds. The Pharmacological Basis of Therapeutics9McGraw-HillNew York50420Google Scholar
- 13.Kuy, A. 1998Farmacotherapeutisch KompasCentrale Medisch Farmaceutische Commissie van de ZiekenfondsraadAmstelveenGoogle Scholar
- 14.George, CF. 1997British National Formulary, September 1997British Medical Association and the Royal Pharmaceutical Society of Great BritainLondonGoogle Scholar
- 16.Anonymous, Anatomical Therapeutic Chemical (ATC)1998Classification Index: Including Defined Daily Doses (DDD) for Plain SubstancesWorld Health OrganizationOslo, NorwayGoogle Scholar
- 20.Schlesselman, JJ. 1982Case–control studiesOxford University PressNew York2006Google Scholar
- 23.Ayd, F. 1961A survey of drug-induced extrapyramidal reactionsJAMA175105560Google Scholar
- 26.Rothman, KJ, Greenland, S. 1998Modern Epidemiology2Lippincott-RavenPhiladelphiaGoogle Scholar